|
|
Cancer Site |
Projected New Cases | ||
|
Total |
Male |
Female | |
|
Lip, Oral Cavity, Pharynx |
955 |
640 |
315 |
|
Tongue |
200 |
140 |
60 |
|
Salivary Glands |
85 |
45 |
40 |
|
Pharynx |
325 |
250 |
75 |
|
Other Parts of the Mouth |
345 |
205 |
140 |
|
Digestive Organs, Peritoneum |
6,995 |
3,655 |
3,340 |
|
Esophagus |
365 |
265 |
100 |
|
Stomach |
690 |
425 |
265 |
|
Small Intestine |
100 |
60 |
40 |
|
Colon, Rectum |
4,380 |
2,155 |
2,225 |
|
Liver, Bile Ducts |
355 |
235 |
120 |
|
Pancreas |
875 |
415 |
460 |
|
Other, Ill-defined Sites |
230 |
100 |
130 |
|
Respiratory System |
5,815 |
3,425 |
2,390 |
|
Larynx |
360 |
285 |
75 |
|
Bronchus, Lung |
5,330 |
3,060 |
2,270 |
|
Other |
125 |
80 |
45 |
|
Bone, Connective, Subcutaneous Tissues |
245 |
130 |
115 |
|
Malignant Melanoma of the Skin |
1,220 |
675 |
545 |
|
Breast |
5,815 |
40 |
5,775 |
|
Genital Organs |
9,040 |
6,490 |
2,550 |
|
Cervix Uteri, Invasive |
395 |
-- |
395 |
|
Corpus Uteri |
1,110 |
-- |
1,110 |
|
Ovary |
750 |
-- |
750 |
|
Other Female Genital |
295 |
-- |
295 |
|
Prostate |
6,245 |
6,245 |
-- |
|
Testis |
200 |
200 |
-- |
|
Other Male Genital |
45 |
45 |
-- |
|
Urinary Organs |
2,480 |
1,695 |
785 |
|
Urinary Bladder |
1,615 |
1,170 |
445 |
|
Kidney, Renal Pelvis |
865 |
525 |
340 |
|
Eye, Lacrimal Gland |
65 |
40 |
25 |
|
Brain, CNS |
520 |
290 |
230 |
|
Endocrine Glands |
515 |
150 |
365 |
|
Thyroid Gland |
475 |
125 |
350 |
|
Other Endocrine Glands |
40 |
25 |
15 |
|
Leukemia |
945 |
525 |
420 |
|
Other Blood and Lymph Tissue |
2,200 |
1,195 |
1,005 |
|
Hodgkin's Disease |
220 |
120 |
100 |
|
Non-Hodgkin's Lymphoma |
1,545 |
850 |
695 |
|
Multiple Myeloma |
435 |
225 |
210 |
|
Other, Unknown |
1,505 |
860 |
645 |
|
All Sites |
38,315 |
19,810 |
18,505 |
Includes all carcinomas of the urinary bladder, but excludes carcinoma in situ of all other sites and common skin cancer.
We believe the projections of new prostate cancer cases are higher than they should be. It is hard to project the number of new cases for this site because of the high incidence rates of the early 90's that resulted from the introduction of the PSA test.